These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30006068)

  • 1. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
    Vermehren J; Park JS; Jacobson IM; Zeuzem S
    J Hepatol; 2018 Nov; 69(5):1178-1187. PubMed ID: 30006068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection.
    Scotto R; Buonomo AR; Moriello NS; Maraolo AE; Zappulo E; Pinchera B; Gentile I; Borgia G
    Rev Recent Clin Trials; 2019; 14(3):173-182. PubMed ID: 30848211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
    Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.
    Mettikanont P; Bunchorntavakul C; Reddy KR
    Aliment Pharmacol Ther; 2019 Mar; 49(5):492-505. PubMed ID: 30687952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of HCV patients in cases of direct-acting antiviral failure.
    Hayes CN; Imamura M; Chayama K
    Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):839-848. PubMed ID: 31392907
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
    Gao LH; Nie QH; Zhao XT
    Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
    Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
    Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing hepatitis C therapy failures and chronic kidney disease.
    Fabrizi F; Messa P
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1135-1142. PubMed ID: 30309263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.
    Berden FA; Aaldering BR; Groenewoud H; IntHout J; Kievit W; Drenth JP
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):349-359. PubMed ID: 27840182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hepatitis C: Results in real life.
    Hézode C
    Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
    Liu CH; Kao JH
    Hepatol Int; 2022 Oct; 16(5):1001-1019. PubMed ID: 35876967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.
    Martinello M; Naggie S; Rockstroh JK; Matthews GV
    Clin Infect Dis; 2023 Aug; 77(Suppl 3):S238-S244. PubMed ID: 37579203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Hepatitis C Virus Infection in Dialysis Patients.
    Kikuchi K
    Contrib Nephrol; 2018; 196():119-122. PubMed ID: 30041215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.
    Sato K; Uraoka T
    World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir and velpatasvir for the treatment of hepatitis C.
    Jackson WE; Everson GT
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):501-505. PubMed ID: 28468532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Two case reports of chronic hepatitis C retreatment].
    Rožnovský L; Mrázek J; Petroušová L; Orságová I; Kabieszová L; Konečná M; Kloudová A
    Klin Mikrobiol Infekc Lek; 2020 Sep; 26(3):96-98. PubMed ID: 33418597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
    Pol S; Parlati L
    Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
    Weisberg IS; Jacobson IM
    Expert Opin Pharmacother; 2017 Apr; 18(5):535-543. PubMed ID: 28092171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
    Gane EJ; Shiffman ML; Etzkorn K; Morelli G; Stedman CAM; Davis MN; Hinestrosa F; Dvory-Sobol H; Huang KC; Osinusi A; McNally J; Brainard DM; McHutchison JG; Thompson AJ; Sulkowski MS;
    Hepatology; 2017 Oct; 66(4):1083-1089. PubMed ID: 28498551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hepatitis C in children and adolescents: how far have we reached?
    Venkatesh V; Seetharaman K; Anushree N
    World J Pediatr; 2023 Feb; 19(2):107-119. PubMed ID: 36129634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.